Blue Owl Capital Holdings LP Purchases Shares of 942,932 Aquestive Therapeutics, Inc. $AQST

Blue Owl Capital Holdings LP acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 942,932 shares of the company’s stock, valued at approximately $3,923,000. Aquestive Therapeutics accounts for about 0.6% of Blue Owl Capital Holdings LP’s holdings, making the stock its 27th largest holding.

A number of other hedge funds have also modified their holdings of AQST. NewEdge Advisors LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at approximately $28,000. BNP Paribas Financial Markets raised its holdings in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after purchasing an additional 4,134 shares during the last quarter. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $33,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Aquestive Therapeutics in the first quarter worth $42,000. Finally, ADAR1 Capital Management LLC lifted its position in shares of Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 264,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Stock Down 2.2%

NASDAQ:AQST opened at $4.49 on Friday. Aquestive Therapeutics, Inc. has a twelve month low of $2.93 and a twelve month high of $7.55. The firm has a market capitalization of $563.55 million, a price-to-earnings ratio of -6.91 and a beta of 1.49. The stock’s 50 day moving average price is $4.17 and its two-hundred day moving average price is $4.12.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million. As a group, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Oppenheimer initiated coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics currently has an average rating of “Buy” and an average target price of $8.50.

Insider Buying and Selling

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total value of $125,500.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at $125,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by corporate insiders.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.